Vilon

Grade D: Preclinical or anecdotal only

TL;DR: Vilon is a synthetic dipeptide (L-Lys-L-Glu, sometimes written KE) developed by Khavinson's group as a thymus-mimetic bioregulator. The published evidence base consists almost entirely of preclinical work in rodents and in vitro models, plus a small number of human observations reported within the Russian bioregulator literature. Animal studies have described extended lifespan in tumor-prone mice, inhibition of transplanted tumor growth, enhanced immune cell activity in aged rodents, and effects on intestinal enzyme activity. One human-relevant publication describes chromatin reactivation in cultured lymphocytes from elderly donors, which is an in vitro observation rather than a clinical finding. A longitudinal study referenced in the broader Khavinson literature followed elderly subjects receiving annual courses of thymic and pineal peptides (including vilon) and reported reduced mortality over several years; however, this was not placebo-controlled, not independently conducted, and specific vilon effects cannot be isolated from the multi-peptide regimen. No randomized, placebo-controlled human trials of vilon have been published. No independent research groups have replicated the animal findings. The evidence does not support any clinical efficacy claim.

Key Takeaways

Grade D: Preclinical or anecdotal only
Not FDA approved: Vilon is not approved by the FDA for any indication and has no approved therapeutic use in the United States or EU. It is available as a research compound. It is not among the peptides currently scheduled for PCAC review, meaning its compounding status remains unresolved without a clear pathway to reclassification in the near term.
Compounding: Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Mechanism

The proposed mechanism follows the general Khavinson bioregulator model: the dipeptide enters cell nuclei and interacts with chromatin, acting as an epigenetic regulator that modulates transcription of genes involved in immune function, cellular aging, and tissue homeostasis. In vitro work supports chromatin interaction in lymphocytes. Whether this translates to meaningful gene expression changes in living humans has not been tested in controlled conditions.

Evidence

Vilon is a synthetic dipeptide (L-Lys-L-Glu, sometimes written KE) developed by Khavinson's group as a thymus-mimetic bioregulator. The published evidence base consists almost entirely of preclinical work in rodents and in vitro models, plus a small number of human observations reported within the Russian bioregulator literature. Animal studies have described extended lifespan in tumor-prone mice, inhibition of transplanted tumor growth, enhanced immune cell activity in aged rodents, and effects on intestinal enzyme activity. One human-relevant publication describes chromatin reactivation in cultured lymphocytes from elderly donors, which is an in vitro observation rather than a clinical finding. A longitudinal study referenced in the broader Khavinson literature followed elderly subjects receiving annual courses of thymic and pineal peptides (including vilon) and reported reduced mortality over several years; however, this was not placebo-controlled, not independently conducted, and specific vilon effects cannot be isolated from the multi-peptide regimen. No randomized, placebo-controlled human trials of vilon have been published. No independent research groups have replicated the animal findings. The evidence does not support any clinical efficacy claim.

Safety and risks

No controlled human safety data exist. The dipeptide structure (two amino acids) is metabolically simple, which is sometimes cited as a basis for presumed tolerability, but this reasoning does not substitute for actual safety trials. Theoretical concerns include immune dysregulation, allergic reactions, and unknown effects with long-term use. The absence of reported adverse events in the uncontrolled Russian literature is not informative about safety.

Compounding legality

Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Sources

Vilon is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).